Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review-Reference-Cited by-同舟云学术

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review

Published:2022-05 Issue:3 Volume:23 Page:195-207
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Cortot Alexis,Le Xiuning,Smit Egbert,Viteri Santiago,Kato Terufumi,Sakai Hiroshi,Park Keunchil,Camidge D. Ross,Berghoff Karin,Vlassak Soetkin,Paik Paul K.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference81 articles.

1. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer;Zheng;Oncotarget,2016

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

3. König D, Savic Prince S, Rothschild SI. Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel). 2021;13:804. doi:10.3390/cancers13040804.

4. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors;Frampton;Cancer Discov,2015

5. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression;Awad;J Clin Oncol,2016

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncommon MET mutational landscape in a non-small cell lung cancer patient treated with crizotinib: Case report;Heliyon;2024-06

2. Effective treatment of MET exon 14 skipping mutation-positive non-small cell lung cancer using capmatinib following serious maculopapular rash caused by two MET inhibitors: a case report;AME Case Reports;2024-04

3. Interstitial pneumonia disease induced by osimertinib combined with savolitinib targeted therapy in a lung cancer patient: A case report;Medicine;2024-01-05

4. MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling;British Journal of Cancer;2023-12-18

5. Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives;Journal of Thoracic Oncology;2023-11